PT - JOURNAL ARTICLE AU - Ziad Taimeh AU - Marshall I Hertz AU - Sara Shumway AU - Marc Pritzker TI - Lung transplantation for pulmonary sarcoidosis. Twenty-five years of experience in the USA AID - 10.1136/thoraxjnl-2015-207497 DP - 2016 Apr 01 TA - Thorax PG - 378--379 VI - 71 IP - 4 4099 - http://thorax.bmj.com/content/71/4/378.short 4100 - http://thorax.bmj.com/content/71/4/378.full SO - Thorax2016 Apr 01; 71 AB - Objective Lung transplantation is the ultimate treatment for end-stage pulmonary sarcoidosis. Post-transplant survival outcomes remain unclear.Methods Survival models were used to assess survival and graft outcomes in patients with sarcoid among 20 896 lung transplants performed in the USA.Results 695 lung recipients were transplanted for pulmonary sarcoidosis. Sarcoid lung recipients had similar median survival rate (69.7 months (IQR 60.2–79.3)) compared with the non-sarcoid lung recipients (63.1 months (IQR 61.4–64.8), p=0.88). In multivariate Cox regression, sarcoidosis was not independently associated with worse mortality (HR 0.96 (95% CI 0.85 to 1.08), p=0.51). Among the sarcoid lung recipients, double lung transplantation (HR 0.76 (0.58 to 0.99), p=0.04) and lung allocation score era (HR 0.74 (0.56 to 0.97), p=0.03) were associated with improved survival.Conclusions Recipients of lung transplants for pulmonary sarcoidosis had similar outcomes compared with non-sarcoid lung recipients.